The recent emergence of B. 1.1. 529, the Omicron variant,, has raised concerns of escape
from protection by vaccines and therapeutic antibodies. A key test for potential …

An increasing proportion of the population has acquired immunity through COVID-19
vaccination and previous SARS-CoV-2 infection, ie, hybrid immunity, possibly affecting the …

The identification of the Omicron (B. 1.1. 529.1 or BA. 1) variant of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) in Botswana in November 2021 1 immediately …

The globally circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variant of concern Omicron (B. 1.1. 529) has a large number of mutations, especially in the …

Recent studies indicated that the strong immune evasion potential of the most recent SARS-
CoV-2 variant, Omicron, results in more frequent reinfections and breakthrough infections …

Abstract The SARS-CoV-2 Omicron BA. 1 variant emerged in 2021 and has multiple
mutations in its spike protein. Here we show that the spike protein of Omicron has a higher …

Abstract The Omicron (B. 1.1. 529) variant of SARS-CoV-2 emerged in November 2021 and
is rapidly spreading among the human population. Although recent reports reveal that the …

Abstract The SARS-CoV-2 Omicron variant has very high levels of transmission, is resistant
to neutralization by authorized therapeutic human monoclonal antibodies (mAb) and is less …

Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1 |
NEJM Skip to main content NEJM Group Follow Us Facebook Twitter Instagram YouTube …

Abstract SARS coronavirus 2 (SARS-CoV-2) continues to evolve and new variants emerge.
Using nationwide Danish data, we estimate the transmission dynamics of SARS-CoV-2 …